News Search Results
Jun 05, 2025, 23:52 ET YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)
SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's
More news about: YolTech Therapeutics
Jun 05, 2025, 16:01 ET AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jun 05, 2025, 15:03 ET Conexwest Expands Single-Phase Cold Storage Lineup: Versatile Solutions for Diverse Temperature Needs
complex electrical infrastructure. With temperature ranges from -20°F to +70°F, they are ideal for industries such as food services, pharmaceuticals, biotechnology, and agriculture.Key Features: Available in 20ft and 40ft sizesTemperature range: -20°F
More news about: Conexwest
Jun 05, 2025, 10:30 ET Oligonucleotide Synthesis Market worth US$24.7 billion by 2030 with 10.8% CAGR | MarketsandMarkets™
market uptake during the studied period. By end user, the oligonucleotide synthesis market includes hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, and CROs & CMOs. In 2024, the hospitals segment accounted for the largest share of the market. The growth
More news about: MarketsandMarkets
Jun 05, 2025, 10:08 ET bitBiome Announces Strategic Partnership with Leading CMO for Manufacturing and Supply of Products
TOKYO, June 5, 2025 /PRNewswire/ -- bitBiome, Inc., a biotechnology company unlocking the potential of our planet's microbes to power the future of the bioeconomy, today announced a new partnership that will enable
More news about: bitBiome
Jun 05, 2025, 09:00 ET QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines
SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised
More news about: QureBio Ltd.
Jun 05, 2025, 09:00 ET Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
Power regulation (Law Decree No. 21/2012) for Scinai's option to acquire 100% of the share capital and voting rights of Pincell S.r.l., an Italian biotechnology company.
More news about: Scinai Immunotherapeutics Ltd.
Jun 05, 2025, 08:30 ET BioDlink Strengthens Global Compliance with Argentina GMP Certification
fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of "innovation + internationalization", At the same time, it explores the extensive application of biotechnology in the field of general health,
More news about: BioDlink Biopharm Co., Ltd.
Jun 05, 2025, 08:00 ET HTL Biotechnology inaugure une nouvelle ligne de production dédiée à l'acide hyaluronique stérile
dermatologie, l'esthétique médicale et la rhumatologie. HTL Biotechnology a récemment renforcé sa position de leader mondial dans le développement de biopolymères de qualité pharmaceutique en acquérant, par l'intermédiaire de sa filiale HTL Biotechnology Innovation Inc. (HTL BII - New
More news about: HTL Biotechnology
Jun 05, 2025, 08:00 ET Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
June 5, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for difficult-to-treat cancers, today announced that the first patient has been dosed in a Phase 1b
More news about: Kazia Therapeutics Limited
Jun 05, 2025, 07:30 ET Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
increased burden for healthcare systems. About Elgan Pharma Elgan Pharma is a late-stage clinical stage, neonatology-focused biotechnology company, dedicated to developing safe, tailored therapies to address medical complications and developmental challenges that are common in preterm
More news about: Elgan Pharma; Chiesi Group
Jun 05, 2025, 07:05 ET REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
and independence, required support for breathing, cardiomyopathy and premature death. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jun 05, 2025, 07:00 ET Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis
Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has been dosed in its Phase 2 WISPer
More news about: Mediar Therapeutics
Jun 05, 2025, 06:30 ET Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced
More news about: Immunic, Inc.
Jun 05, 2025, 06:00 ET Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results
clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution
More news about: Waterdrop Inc.
Jun 04, 2025, 19:00 ET Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding
DIEGO, June 4, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256,
More news about: Rakuten Medical, Inc.
Jun 04, 2025, 16:59 ET Dynavax Comments on Glass Lewis Recommendation
as Dynavax has delivered 203% total return to stockholders over the last five years2 while vaccine peers returned 9% and the S&P Biotechnology Select Industry Index declined 17% over the same period.Dynavax is one of the few vaccine companies that has returned
More news about: Dynavax Technologies
Jun 04, 2025, 10:45 ET MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the Loitering Munition Quadrant Report 2025
Arquimea is a technology-driven company committed to developing cutting-edge products and solutions across the aerospace and defense, biotechnology, and big science sectors. With a strong focus on solving complex societal challenges, the company reinvests a significant portion of its annual
More news about: MarketsandMarkets
Jun 04, 2025, 09:30 ET DPX Technologies Announces New Automated Workflows and Expanded Liquid Handler Compatibility for Genomic Testing
COLUMBIA, S.C., June 4, 2025 /PRNewswire/ -- DPX Technologies, a biotechnology company providing solutions for automated sample preparation, announces their latest products and fully automated workflows utilizing functionalized
More news about: DPX Technologies
Jun 04, 2025, 08:31 ET MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
June 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting pre-clinical data on DA-1241, a novel G-Protein-Coupled
More news about: MetaVia Inc.
Jun 04, 2025, 08:00 ET Repertoire Immune Medicines Appoints Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer and Advances TCR Bispecific Development Candidate Toward the Clinic
Mass., June 4, 2025 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced the appointment of Robert
More news about: Repertoire Immune Medicines
Jun 04, 2025, 07:41 ET SCbio Showcases South Carolina's Life Sciences Surge at Annual BIO Convention in Boston
BIO 2025, the annual international convention hosted by Biotechnology Innovation Organization June 16-19 in Boston.
More news about: SCbio
Jun 04, 2025, 05:38 ET BPC Instruments receives orders from KU Leuven valued at 0.7 MSEK
instruments enabling more efficient, reliable, and higher quality research and analysis for industries in renewable bioenergy and environmental biotechnology. The result is not only higher accuracy and precision, but also a significant reduction in time consumption and labor requirement for performing
More news about: BPC Instruments AB
Jun 04, 2025, 03:30 ET Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board
spent 34 years at Novo Nordisk, most recently as Corporate Vice President and Head of Biotechnology. During this time, he was responsible for building and heading a 240+ employee international protein-biotechnology organisation and he established the first international biopharmaceutical R&D centre
More news about: Commit Biologics
Jun 03, 2025, 18:54 ET BioVaxys Issues Corporate Update
to acquire the entire portfolio of assets and intellectual property based on the DPX immune educating platform technology developed by Canadian biotechnology company, IMV Inc. The May 2025 Amendment lowers a performance milestone provision in the original APA for BioVaxys
More news about: BioVaxys Technology Corp.